Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenkun Ma

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Disease Markers|November 18, 2020
CD82 Suppresses ADAM17-Dependent E-Cadherin Cleavage and Cell Migration in Prostate CancerZhenkun Ma, Ye Gao, Wei Liu, et al.
ACS Medicinal Chemistry Letters|February 19, 2021
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced SolubilityAndrew M Thompson, Patrick D O'Connor, Vanessa Yardley, et al.
Oncotarget|May 6, 2015
Infiltrated pre-adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-β1/Smad/MMP9 signalsHongjun Xie, Lei Li, Guodong Zhu, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 2015
Reciprocal regulation of hypoxia-inducible factor 2α and GLI1 expression associated with the radioresistance of renal cell carcinomaJiancheng Zhou, Kaijie Wu, Dexuan Gao, et al.
Journal of Medicinal Chemistry|February 23, 2016
Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Adrian Blaser, et al.
Molecules (Basel, Switzerland)|April 19, 2012
Systematic evaluation of structure-activity relationships of the riminophenazine class and discovery of a C2 pyridylamino series for the treatment of multidrug-resistant tuberculosisBinna Liu, Kai Liu, Yu Lu, et al.
Bioorganic & Medicinal Chemistry Letters|May 3, 2017
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseasesAndrew M Thompson, Adrian Blaser, Brian D Palmer, et al.
Molecules (Basel, Switzerland)|May 28, 2020
Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic BacteriaZhijun Zhuang, Dawei Wan, Jun Ding, et al.
European Journal of Medicinal Chemistry|December 3, 2020
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisalAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
Journal of Medicinal Chemistry|February 21, 2018
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Disease Markers|November 18, 2020
CD82 Suppresses ADAM17-Dependent E-Cadherin Cleavage and Cell Migration in Prostate CancerZhenkun Ma, Ye Gao, Wei Liu, et al.
ACS Medicinal Chemistry Letters|February 19, 2021
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced SolubilityAndrew M Thompson, Patrick D O'Connor, Vanessa Yardley, et al.
Oncotarget|May 6, 2015
Infiltrated pre-adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-β1/Smad/MMP9 signalsHongjun Xie, Lei Li, Guodong Zhu, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 2015
Reciprocal regulation of hypoxia-inducible factor 2α and GLI1 expression associated with the radioresistance of renal cell carcinomaJiancheng Zhou, Kaijie Wu, Dexuan Gao, et al.
Journal of Medicinal Chemistry|February 23, 2016
Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Adrian Blaser, et al.
Molecules (Basel, Switzerland)|April 19, 2012
Systematic evaluation of structure-activity relationships of the riminophenazine class and discovery of a C2 pyridylamino series for the treatment of multidrug-resistant tuberculosisBinna Liu, Kai Liu, Yu Lu, et al.
Bioorganic & Medicinal Chemistry Letters|May 3, 2017
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseasesAndrew M Thompson, Adrian Blaser, Brian D Palmer, et al.
Molecules (Basel, Switzerland)|May 28, 2020
Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic BacteriaZhijun Zhuang, Dawei Wan, Jun Ding, et al.
European Journal of Medicinal Chemistry|December 3, 2020
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisalAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
Journal of Medicinal Chemistry|February 21, 2018
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
Pageof 7